The 8 Blood Markers Every Man on GLP-1 or TRT Should Track Quarterly

If you're on GLP-1 medications or testosterone therapy, regular bloodwork isn't optional — it's how you know your treatment is working and your body is handling it safely. These are the eight markers worth tracking every quarter.

Marker 1: Total Testosterone

What it tells you: The total amount of testosterone in your blood, including both bound (to SHBG and albumin) and free fractions. This is the standard screening test for hypogonadism.

Optimal range: 450–900 ng/dL for most men (reference ranges vary by lab). Below 300 ng/dL is generally considered the threshold for clinical hypogonadism.

Why it matters for GLP-1 users: Weight loss on GLP-1 medications can increase total testosterone by reducing aromatase-mediated conversion to estradiol. Tracking this marker shows whether your weight loss is producing the expected hormonal improvement.

Why it matters for TRT users: Confirms your dose is producing adequate levels. Too low means underdosing; too high increases side effect risk.

When to test: Morning (before 10 AM) for the most accurate reading. Testosterone has a diurnal pattern — levels peak in the morning and can be 20–30% lower in the afternoon.

Marker 2: Free Testosterone

What it tells you: The fraction of testosterone that's unbound and biologically active. Only about 2–3% of total testosterone circulates as free T.

Why it matters: A man can have normal total testosterone but low free testosterone if his SHBG (sex hormone-binding globulin) is elevated. SHBG binds testosterone, making it unavailable. This is common in men with liver disease, thyroid issues, or aging. Free T is a better indicator of what your body can actually use.

Optimal range: Varies by lab method, but generally 50–200 pg/mL for calculated free testosterone.

Marker 3: Estradiol (E2)

What it tells you: Your estrogen level. In men, estradiol is produced primarily by aromatase conversion of testosterone in fat tissue.

Why it matters for GLP-1 users: As you lose weight, aromatase activity decreases. You should see estradiol trend downward while testosterone trends upward — a direct marker of the metabolic improvement GLP-1 weight loss provides.

Why it matters for TRT users: TRT increases substrate for aromatase. Some men on TRT see estradiol climb too high, causing water retention, mood changes, and gynecomastia (breast tissue growth). Monitoring E2 helps catch this early.

Optimal range: 20–40 pg/mL for most men on TRT. Below 20 can cause joint pain and low libido; above 50 may cause side effects.

Marker 4: HbA1c

What it tells you: Your average blood sugar over the past 2–3 months. Unlike fasting glucose (a snapshot), HbA1c reveals the bigger picture.

Optimal: Below 5.7% is normal. 5.7–6.4% is prediabetic. 6.5%+ is diabetic.

Why it matters for GLP-1 users: GLP-1 medications improve glycemic control. Tracking HbA1c shows whether your metabolic improvement is real and sustained. Many men see their HbA1c drop from prediabetic ranges to normal within 3–6 months on GLP-1 therapy.

Marker 5: Fasting Insulin

What it tells you: How hard your pancreas is working to manage blood sugar. Elevated fasting insulin (hyperinsulinemia) is the earliest sign of insulin resistance — years before glucose or HbA1c start climbing.

Optimal: Below 5 µIU/mL is ideal. Above 10 suggests insulin resistance. Above 15 is a significant metabolic red flag.

Why most panels miss it: Standard metabolic panels don't include fasting insulin. You often need to specifically request it. It costs an extra $15–$30 but provides information no other marker captures at this early stage.

Marker 6: Lipid Panel

What it tells you: Cardiovascular risk via LDL cholesterol, HDL cholesterol, and triglycerides.

Key ratios:

• Triglycerides/HDL ratio: Below 2.0 is ideal; above 3.5 strongly correlates with insulin resistance
• LDL: Below 100 mg/dL is optimal for most men; below 70 for men with established cardiovascular disease
• HDL: Above 40 mg/dL minimum; above 50 is ideal for men

GLP-1 impact: Semaglutide and tirzepatide both improve lipid profiles significantly — reducing LDL and triglycerides while modestly increasing HDL. The SELECT trial demonstrated a 20% reduction in cardiovascular events with semaglutide.

Marker 7: CBC with Hematocrit

What it tells you: Complete blood count, with special attention to hematocrit (the percentage of your blood that's red blood cells).

Why it matters for TRT users: Testosterone stimulates red blood cell production (erythropoiesis). Elevated hematocrit (polycythemia) is the most common side effect of TRT, increasing blood viscosity and stroke risk. Hematocrit above 54% typically warrants intervention — dose reduction, therapeutic phlebotomy (blood donation), or treatment modification.

Monitoring frequency: Check at baseline, 3 months, 6 months, and every 6–12 months thereafter on stable TRT. More frequent monitoring if hematocrit is trending up.

Marker 8: Liver & Kidney Function

What it tells you: Whether your liver and kidneys are handling your medications and metabolic changes appropriately.

Key markers:

• ALT and AST: Liver enzymes. Mild elevations can occur with weight loss (fatty liver releasing stored fat). Significant elevations warrant investigation.
• Creatinine and BUN: Kidney function markers. GLP-1 medications are generally kidney-protective, but hydration status affects these values, and GLP-1 users are at higher dehydration risk.

GLP-1 benefit: Weight loss on GLP-1 therapy often improves liver enzymes by reducing hepatic fat (NAFLD/MASLD resolution). Many men see elevated ALT normalize as they lose weight.

The Quarterly Lab Checklist

Total self-pay cost for the complete panel: approximately $130–$275 per quarter. Many telehealth providers include labs in their program pricing or partner with direct-to-consumer lab services (Quest, Labcorp) for discounted rates.